Welcome to our dedicated page for Bio Rad Labs news (Ticker: BIO), a resource for investors and traders seeking the latest updates and insights on Bio Rad Labs stock.
Bio-Rad Laboratories, Inc. (BIO) delivers essential innovations in clinical diagnostics and life science research through its global operations. This dedicated news hub provides investors and industry professionals with timely access to official announcements, financial updates, and scientific advancements.
Discover comprehensive collection of press releases covering quarterly earnings, regulatory milestones, product launches, and strategic partnerships. Our curated feed ensures transparent access to BIO's operational developments across its dual focus areas: laboratory-quality diagnostic systems and cutting-edge research tools.
Key updates include innovations in digital PCR technology, quality control solutions for clinical testing, and advancements supporting biopharmaceutical development. Bookmark this page for direct access to primary-source information affecting BIO's market position and research impact.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) will report its financial results for Q3 2021 on October 28, 2021, after market close. A conference call will follow at 2 PM PT to discuss the results. Interested parties can listen by calling 844-200-6205 in the U.S. or 929-526-1599 internationally, using access code: 535686. The results and further details can be accessed on the company’s website. Bio-Rad, established in 1952, exceeded $2.5 billion in revenue in 2020 and operates worldwide with approximately 7,800 employees.
Bio-Rad Laboratories (NYSE: BIO) announced participation in a Fireside Chat at the 2021 Virtual Wells Fargo Healthcare Conference on September 9 at 11:40 AM (Pacific Time). Interested parties can access the live webcast via the Investor Relations section of bio-rad.com. Bio-Rad, a leader in life science research and clinical diagnostics, reported over $2.5 billion in revenue in 2020 and has been operational since 1952. Headquartered in
Bio-Rad Laboratories reported strong Q2 2021 financial results, with net sales of $715.9 million, up 33.4% from Q2 2020. The Life Science segment sales rose 32.6% to $334.2 million, while Clinical Diagnostics grew 34.3% to $380.2 million. Gross margin improved to 56.1% from 54.6% a year earlier. Net income was $914.1 million, or $30.32 per share, impacted by equity security valuations. The company updated its 2021 outlook, forecasting 10.0% to 10.5% non-GAAP currency-neutral revenue growth.
Bio-Rad Laboratories (NYSE: BIO and BIOb) announced a final settlement with 10x Genomics (Nasdaq: TXG) to resolve multiple litigations across various regions, including Massachusetts and Germany. This settlement includes a global patent cross-license, granting Bio-Rad broad freedom-to-operate in the single-cell genomics market, along with past and future royalties. Both companies maintain their patent rights, affirming their validity. The CEO of Bio-Rad expressed satisfaction over the resolution, highlighting the value of the company's intellectual property rights.
Bio-Rad Laboratories (NYSE: BIO, BIOb) will announce its Q2 2021 financial results on July 29, 2021, after market close. The results will be discussed in a conference call at 3 PM PT (6 PM ET). Investors can listen in by calling 855-779-9068 in the U.S. or 631-485-4862 internationally, with a passcode of 5382265. A webcast will also be available on the company’s website under “Quarterly Results” and will remain accessible for one year. Bio-Rad, based in Hercules, California, reported revenues of over $2.5 billion in 2020.
Bio-Rad Laboratories (NYSE: BIO, BIOb) has partnered with Seegene, Inc. to develop and commercialize infectious disease molecular diagnostic products. Seegene will supply diagnostic tests for Bio-Rad's CFX96™ Dx Real-Time PCR System, pending FDA clearance. The partnership aims to enhance diagnostic testing in U.S. markets. Seegene's assays are noted for their multiplex capabilities, detecting up to seven infectious disease targets simultaneously with results available in about four hours. This collaboration aligns with Bio-Rad's mission to improve healthcare through innovative diagnostic solutions.
Bio-Rad Laboratories (NYSE: BIO, BIOb) launched the PREvalence™ ddPCR® SARS-CoV-2 Wastewater Quantification Kit, designed to accurately detect SARS-CoV-2 in wastewater, offering a cost-effective early warning system for communities. This kit can identify the virus days to weeks before individual testing, aligning with CDC recommendations. It integrates with Bio-Rad’s existing platforms, enhancing their COVID-19 product portfolio. Bio-Rad emphasizes its commitment to supporting public health amid the ongoing pandemic.
Bio-Rad Laboratories (NYSE: BIO, BIOb) announced that key executives, including President and CEO Norman Schwartz, will participate in a Fireside Chat at the Jefferies Virtual Healthcare Conference on June 2 at noon PT. The event will provide insights into the company's strategies and initiatives. A live webcast link will be available on their Investor Relations page.
Bio-Rad Laboratories reported Q1 2021 net sales of $726.8 million, a 27.1% increase from $571.6 million in Q1 2020. Life Science segment sales rose 61.3% to $366.5 million, driven by COVID-19 product demand. Clinical Diagnostics segment sales increased 5.4% to $358.5 million. Net income surged to $977.4 million ($32.38 per share) from $685.9 million ($22.72 per share) in the previous year. The company expects 5.5% to 6.0% currency-neutral revenue growth for the year. Gross margin slightly declined to 55.1% from 55.5%.
Bio-Rad Laboratories, Inc. (NYSE: BIO, BIOb) will announce its financial results for the first quarter of 2021 on April 29, 2021, after market close. A conference call to discuss these results is scheduled for 3 PM PT (6 PM ET). Investors can participate by calling 855-779-9068 in the U.S. or 631-485-4862 internationally, using the passcode 4692298. Additionally, the call will be available live via a webcast on the company's website.
